⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 1, 2024Cancer MedicineOpen Access

PD‐1 inhibition with retifanlimab and/or arginase inhibition with INCB001158 in Japanese patients with solid tumors: A phase I study

Yasutoshi Kuboki Takafumi Koyama Nobuaki Matsubara Yoichi Naito Shunsuke Kondo Kenichi Harano Kan Yonemori Kiyotaka Yoh Yuan Gu Tetsuya Mita Xuejun Chen Eiji Ueda Noboru Yamamoto Toshihiko Doi Toshio Shimizu

View Full Paper

Ask AI

Bookmark

Share

Abstract

Retifanlimab is a humanized monoclonal antibody targeting programmed death protein-1, and INCB001158 is an oral arginase inhibitor. This phase Ib study investigated retifanlimab, INCB001158, and their combination in Japanese patients with advanced solid tumors.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kuboki et al. (2024) studied this question.

synapsesocial.com/papers/68e70daab6db6435876877d9 https://doi.org/10.1002/cam4.6980

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101)2024 · 25 citations
2Phase II study of retifanlimab in patients with recurrent locally advanced or metastatic Merkel cell carcinoma (POD1UM-201)2025 · 16 citations
3FDA Approval Summary: Retifanlimab for the treatment of adult patients with metastatic or inoperable locally recurrent squamous cell carcinoma of the anal canalReview · 2026
4An evaluation of retifanlimab-dlwr with carboplatin and paclitaxel and as a single agent for squamous cell carcinoma of the anal canalLate-Phase Clinical Trial · 2026
5Antitumor activity and safety of the PD-1 inhibitor retifanlimab in patients with recurrent microsatellite instability-high or deficient mismatch repair endometrial cancer: Final safety and efficacy results from cohort H of the POD1UM-101 phase I study2024 · 8 citations

More related papers

First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumours2024
FDA greenlights retifanlimab combo and monotherapy for advanced anal cancer: a new era in anal squamous cell carcinoma treatment2025
A phase 1/1b, open-label, dose-escalation study of PD-1 inhibitor, cetrelimab alone and in combination with FGFR inhibitor, erdafitinib in Japanese patients with advanced solid tumors2024

More from Cancer Medicine

MGP_HNSC32: A H&E Morphology‐Derived 32‐Gene Prognostic Signature in Head and Neck Squamous Cell CarcinomaSun,
Pre‐Existing and Post‐Cancer Major Cardiovascular Disease and Their Association With Mortality Outcomes Among Cancer Survivors in AustraliaThu,